High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine. Academic Article uri icon



  • PURPOSE: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. METHODS: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. RESULTS: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P = .01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. CONCLUSION: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.


  • Wilkin, Timothy
  • Lee, Jeannette Y
  • Lensing, Shelly Y
  • Stier, Elizabeth A
  • Goldstone, Stephen E
  • Berry, Michael J
  • Jay, Naomi
  • Aboulafia, David M
  • Einstein, Mark H
  • Saah, Alfred
  • Mitsuyasu, Ronald T
  • Palefsky, Joel M

publication date

  • March 1, 2013



  • Acquired Immunodeficiency Syndrome
  • Anus Neoplasms
  • Carcinoma in Situ
  • HIV-1
  • Papillomavirus Vaccines
  • Vaccination


PubMed Central ID

  • PMC3676177

Scopus Document Identifier

  • 84878844175

Digital Object Identifier (DOI)

  • 10.1310/hct1402-75

PubMed ID

  • 23611828

Additional Document Info


  • 14


  • 2